Jiangxi Jemincare Group Co. Ltd.

Advice for CEOs and CFOs as they navigate the year ahead

BioCentury’s final Public Equity Report of the year tallies up fundraising activity

Wuxi Apptec moves to preserve its core interests, GLP-1R deals showcase breadth of China biotech’s dealmaking

A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine

BioCentury’s East-West conference survey finds wariness about near-term global drug development; cross-border deals might be the outlier

Roche partnering head gives advice to biotechs seeking pharma deals on The BioCentury Show

Over half of the cancer therapies Chinese companies out-licensed in 2021-22 employ new modalities or unapproved targets

Genentech paying Shanghai biotech $60 million up front for global rights to androgen receptor degrader